4/26
07:05 am
ymab
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
Low
Report
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
4/25
04:08 pm
ymab
Y-mAbs to Present at 2024 ASCO Annual Meeting [Yahoo! Finance]
Low
Report
Y-mAbs to Present at 2024 ASCO Annual Meeting [Yahoo! Finance]
4/25
04:05 pm
ymab
Y-mAbs to Present at 2024 ASCO Annual Meeting
Low
Report
Y-mAbs to Present at 2024 ASCO Annual Meeting
4/19
07:57 am
ymab
New Strong Buy Stocks for April 19th [Yahoo! Finance]
Low
Report
New Strong Buy Stocks for April 19th [Yahoo! Finance]
4/18
09:28 am
ymab
Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161% [Yahoo! Finance]
Low
Report
Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161% [Yahoo! Finance]
3/20
09:19 am
ymab
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains? [Yahoo! Finance]
Medium
Report
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains? [Yahoo! Finance]
3/14
09:13 am
ymab
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer [Yahoo! Finance]
Medium
Report
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer [Yahoo! Finance]
3/14
09:05 am
ymab
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Medium
Report
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
3/6
08:09 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.
3/5
01:18 pm
ymab
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice [Yahoo! Finance]
Low
Report
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice [Yahoo! Finance]
3/4
10:18 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at Canaccord Genuity Group Inc. from $22.00 to $26.00. They now have a "buy" rating on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at Canaccord Genuity Group Inc. from $22.00 to $26.00. They now have a "buy" rating on the stock.
3/4
09:16 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at BMO Capital Markets from $16.00 to $26.00. They now have an "outperform" rating on the stock.
High
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at BMO Capital Markets from $16.00 to $26.00. They now have an "outperform" rating on the stock.
3/4
08:56 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/4
07:43 am
ymab
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors [Yahoo! Finance]
Medium
Report
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors [Yahoo! Finance]
3/4
07:30 am
ymab
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
Medium
Report
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
2/29
04:51 pm
ymab
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
High
Report
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
2/29
04:26 pm
ymab
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments [Yahoo! Finance]
High
Report
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments [Yahoo! Finance]
2/29
04:05 pm
ymab
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
High
Report
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
2/20
08:12 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at HC Wainwright from $11.00 to $21.00. They now have a "buy" rating on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target raised by analysts at HC Wainwright from $11.00 to $21.00. They now have a "buy" rating on the stock.
2/16
07:30 am
ymab
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
Medium
Report
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
2/13
06:19 am
ymab
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last? [Yahoo! Finance]
2/12
06:18 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, up previously from $12.00.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, up previously from $12.00.
1/29
02:57 pm
ymab
Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation [Yahoo! Finance]